Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Nanocarrier drug delivery with light for sarcoma

Studies a light-guided nanocarrier drug delivery method for sarcoma tumors.

Plain-language title generated from the registry record
Registry title: Innovative Drug Delivery Nanophotonic Platform for Implementation of Sarcoma Therapy

Key facts

Where
Bologna and Meldola, ItalySee the 2 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 85 years old?

Source: NCT06599957, who can take part

Where in Italy

  • Istituto Ortopedico Rizzoli-OSOTTBologna, ItalyTaking people
  • IRCCS - Istituto Romagnolo per lo Studio Dei Tumori, Dino AmadoriMeldola, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Istituto Ortopedico Rizzoli
Trial code
NCT06599957
Record updated
22 September 2025
Original description
DEEPLY aims to improve sarcoma therapy by the development of an innovative nanophotonic delivery approach to be applied in the future as an integrated local therapy for patients with inoperable tumors or with oligometastases. The major aim of the project is the development of innovative nanocarriers loaded with chemotherapeutic agents, whose delivery will be improved by the use of an optic fiber (optoporation). After the synthesis, and characterization of NPs, a prototype will be produced and preclinically validated on patient-derived biological material. This wide comprehensive methodological approach will ensure the obtainment of robust data to be faster exploited toward clinical applications.Read full original descriptionShow less

Innovative Drug Delivery Nanophotonic Platform for Implementation of Sarcoma Therapy

DEEPLY aims to improve sarcoma therapy by the development of an innovative nanophotonic delivery approach to be applied in the future as an integrated local therapy for patients with inoperable tumors or with oligometastases. The major aim of the project is the development of innovative nanocarriers loaded with chemotherapeutic agents, whose delivery will be improved by the use of an optic fiber (optoporation). After the synthesis, and characterization of NPs, a prototype will be produced and preclinically validated on patient-derived biological material. This wide comprehensive methodological approach will ensure the obtainment of robust data to be faster exploited toward clinical applications.

Inclusion: Patients eligible for the study will be male or female, with an age ranging from 0- to 85 years, undergoing surgery or biopsy for STSs or BSs including osteosarcomas; Included patients may have undergone or may be still in treatment with chemotherapy (also neo-adjuvant settings), targeted therapy, radiotherapy, or combination therapy; IRST will enroll only adult patients (age \> 18 years); Signed informed consent from all subjects enrolled in the study. IOR patients will have to sign both the specific project Informed Consent and the IOR Biobank Informed consent.

Exclusion: Patients not affected by STSs or BSs will be excluded from the study, as well as patients with multiple primary tumors.

ClinicalTrials.gov NCT06599957